Results 161 to 170 of about 12,460 (212)
Recurrent Candida parapsilosis Complex Endocarditis in a Patient With a Mechanical Mitral Prosthetic Valve Managed Conservatively in a Resource-Limited Setting: A Case Report. [PDF]
CureusVilleda WA +3 more
europepmc +1 more source
Successful Management of <i>Candida auris</i> Bloodstream Infection in an Elderly Patient: A Case Report. [PDF]
Clin Case RepChowdhury AH +8 more
europepmc +1 more source
Echinocandins in invasive candidiasis
Mycoses, 2013 SummaryWe summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managingIC. The echinocandins have demonstrated good activity against non‐albicansinfections and also azole‐resistant strains, both preclinically and in recent clinical trials.
Hsin-Yun Sun +2 more
exaly +5 more sources
Echinocandins as Biotechnological Tools for Treating Candida auris Infections
Journal of Fungi (Basel, Switzerland), 2020 Candida auris has been reported in the past few years as an invasive fungal pathogen of high interest. Its recent emergence in healthcare-associated infections triggered the efforts of researchers worldwide, seeking additional alternatives to the use of ...
Elizabete De Souza Cândido +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacotherapy, 2007
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
exaly +3 more sources
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
exaly +3 more sources
Pediatric Infectious Disease Journal, 2011
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Jill A, Hoffman, Thomas J, Walsh
openaire +4 more sources
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Jill A, Hoffman, Thomas J, Walsh
openaire +4 more sources
In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris [PDF]
Antibiotics, 2021 Candida auris is an emergent fungal pathogen that causes severe infectious outbreaks globally. The public health concern when dealing with this pathogen is mainly due to reduced susceptibility to current antifungal drugs.
Sarah Kim +2 more
exaly +2 more sources